5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
NCT05385549
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG:
Imatinib Mesylate
Sponsor
Asan Medical Center